Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,036.90down ₹31.90 (2.98%)BSE ₹1,037.80
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
52-week range of traded prices to 2 Nov 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,07,98637.7% delivered
Strides Pharma Science share news and announcements
1,447 announcements, routine notices left out, newest first. Page 26 of 29.
Feb 2010
11 Feb · Updates
Abstract and Memorandum of Interest pursuant to Section 302 of the Companies Act, 1956 informing appointment of Executive Director. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Feb · Business
Press release dated February 09, 2010, titled "Strides Arcolab Announces USFDA Approval For Labetalol Hydrochloride Injection, USP - Total Approvals in Sterile Space at 18." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
25 Jan · Grant of Options
The Compensation Committee of the Company has granted 137,500 options under the Stride Arcolab ESOP 2008 at Rs.225.65 per option (exercise price), to few eligible Employees of the Company. The shares covered by such options are 137,500 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting20 Jan · Allotment of Equity Shares
Subsequent to the receipt of the requisite Court approvals for the amalgamation of Global Remedies Limited (GRL), Grandix Pharmaceuticals Limited (GPL), Grandix Laboratories Limited (GLL), Quantum Remedies Private Limited (QRPL) with Strides Acrolab Limited, the Company has allotted 13,524 fully paid equity shares of Rs. 10/- to the erstwhile shareholders of GPL and GLL. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 402,156,140 consisting of 40,215,614 equity shares of Rs. 10/- each to Rs. 402,291,380 consisting of 40,229,138 equity shares of Rs. 10/- each.20 Jan · Business
Mr. V. S. Iyer has been appointed as an Executive Director of the Company effective January 19, 2010. Further the Company has submitted a copy of press release on this regard. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jan · Results
Company will declare and publish the Audited Financial Results for the financial year ended December 31, 2009 before March 31, 2010. In view of the same, the Company would not be declaring and publishing the Unaudited Financial Results for the last quarter ended December 31, 2009 during the month of January, 2010.7 Jan · Business
Press release dated January 06, 2010, titled "Pfizer and Strides Arcolab to Collaborate on Generic Products." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
28 Dec · Updates
The Company has purchased USD 1.5 Million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion16 Dec · Updates
The "Company has purchased USD 0.50 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion."11 Dec · Business
Press release dated December 11, 2009, titled " Strides Arcolab Announces Conclusion of Court Process for Merger." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Dec · Legal
Strides Arcolab Limited had informed the Exchange that the Company has purchased USD 1,500,000 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion. Now the Company has clarified that "The Company has purchased 'USD 1.5 Million' aggregate face value of bonds and not 'USD 1,500,000 Million' as stated in the release."11 Dec · Updates
Company has purchased USD 1,500,000 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion.4 Dec · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Dec · Allotment of Equity Shares
Company has allotted 30,000 fully paid equity shares of Rs. 10/- each under Strides Arcolab ESOP 2006 Scheme.Consequent to allotment, the paid up equity share capital of the Company has increased from Rs.401,856,140 consisting of 40,185,614 equity shares of Rs. 10/- each to Rs. 402,156,140 consisting of 40,215,614 equity shares of Rs.10/- each.
Nov 2009
30 Nov · Allotment of Equity Shares
Company has allotted 30,000 fully paid equity shares of Rs.10/- each under Strides Arcolab ESOP 2006 Scheme. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 401,556,140 consisting of 40,155,614 equity shares of Rs. 10/- each to Rs. 401,856,140 consisting of 40,185,614 equity shares of Rs.10/- each.24 Nov · News Verification
News Verification : The media had reports that private equity firm General Atlantic may buy a significant minority stake in Strides Arcolab Limited 's injectables business arm for around $100 million. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Strides Arcolab Limited has vide its letter inter-alia stated,"We wish to state that the news is purely speculative in nature and we will keep the stock exchanges informed as and when there is any development."
Oct 2009
30 Oct · Business
Press release dated October 30, 2009, titled "Financial Performance Q3-2009; Revenue up by 17%; EBITDA up by 134%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 16578.79 lacs for quarter ending on 30-SEP-2009 against Rs. 16632.34 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 423.25 lacs for the quarter ending on 30-SEP-2009 against Rs. (5167.61) lacs for the quarter ending on 30-SEP-2008.30 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 31714.42 lacs for quarter ending on 30-SEP-2009 against Rs. 27210.33 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 1973.38 lacs for the quarter ending on 30-SEP-2009 against Rs. 10534.9 lacs for the quarter ending on 30-SEP-2008.20 Oct · Board meeting
Meeting on 30 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”14 Oct · Results
Based on the Scrutinizer's Report dated October 14, 2009, the resolutions seeking approval of the shareholders through Postal Ballot concerning the following matters have been carried out with requisite majority. (1) Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 for transfer of R&D Business of the Company to Strides Specialties Private Limited, a wholly owned subsidiary of the Company. (2) Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 for Mortgage and/or charge of movable and immovable properties of the company14 Oct · Updates
Strides Arcolab Limited (the "Company") wishes to inform the exchange that the Company has purchased USD 2.0 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion.8 Oct · Updates
The Hon'ble High Court of Judicature at Bombay has sanctioned the Composite Scheme of Arrangement between Grandix Pharmaceuticals Limited, Grandix Laboratories Limited, Global Remedies Limited and Quantum Remedies Private Limited ('Transferor Companies') with Strides Arcolab Limited (Transferee Company). The approvals from Hon'ble High Courts of Karnataka and Chennai are awaited
Sep 2009
25 Sep · Business
Press release dated September 25, 2009, titled "Strides Arcolab announces the retail launch of Starflu (OSELTAMIVIR) for the treatment of 'Influenza - A (H1N1)'". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Sep · Meeting
Notice of Postal Ballot (along with explanatory statement) seeking approval of the shareholders for : 1. Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 for transfer of R&D Business of the Company to Strides Specialties Private Limited, a wholly owned subsidiary of the Company; 2. Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 for Mortgage and/or charge of movable and immovable properties of the company. The copy of the Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Sep · Business
Press release dated September 01, 2009, titled "Strides Arcolab Limited receives order from Government of India for the supply of Oseltamivir Capsules for the treatment of 'Influenza-A (H1N1)' ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
28 Aug · Grant of Options
Remuneration Committee of the Company on August 27, 2009 has granted 2,42,500 options under the Strides Arcolab ESOP 2008 at Rs. 132.65 per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 2,42,500 equity shares. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting.27 Aug · Allotment of Equity Shares
Company has allotted 58,600 fully paid equity shares of Rs. 10/- each under Strides Arcolab ESOP 2008 Scheme. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 400,970,140 consisting of 40,097,014 equity shares of Rs. 10/- each to Rs. 401,556,140 consisting of 40,155,614 equity shares of Rs. 10/- each.26 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Aug · Allotment of Equity Shares
The Company has allotted 47,000 fully paid equity shares of Rs.10 each under Strides Arcolab ESOP 2008 Scheme. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs.40,05,00,140 consisting of 4,00,50,014 equity shares of Rs.10/- each to Rs.40,09,70,140 consisting of 4,00,97,014 equity shares of Rs.10/- each11 Aug · Business
Press release dated August 11, 2009, titled "Strides Arcolab Limited Fully geared to meet demand for supply of drugs for Influenza - A (H1N1) Pandemic". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
30 Jul · Business
Press release dated July 30, 2009 titled "Financial Performance Q2-2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements. For more details click here.30 Jul · Results
Consolidated Results for the half year ended on 30-JUN-2009 as follows: Net Sales of Rs. 59401.31 lacs for half year ending on 30-JUN-2009 against Rs. 46233.1 lacs for the half year ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 5225.21 lacs for the half year ending on 30-JUN-2009 against Rs. 375.09 lacs for the half year ending on 30-JUN-2008.30 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 30975.54 lacs for quarter ending on 30-JUN-2009 against Rs. 25535.33 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 4177.03 lacs for the quarter ending on 30-JUN-2009 against Rs. (4884.26) lacs for the quarter ending on 30-JUN-2008.30 Jul · Results
Standalone Results for the half year ended on 30-JUN-2009 as follows: Net Sales of Rs. 34516.49 lacs for half year ending on 30-JUN-2009 against Rs. 28046.21 lacs for the half year ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 8160.74 lacs for the half year ending on 30-JUN-2009 against Rs. (7200.91) lacs for the half year ending on 30-JUN-2008.30 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 17540.67 lacs for quarter ending on 30-JUN-2009 against Rs. 16077.45 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 6012.61 lacs for the quarter ending on 30-JUN-2009 against Rs. (5596.11) lacs for the quarter ending on 30-JUN-2008.20 Jul · Board meeting
Meeting on 30 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”10 Jul · Re-pricing of Stock Options
Consequent to the approval by the shareholders through postal ballot on June 23, 2009, inter alia for the re-pricing of the Stock Options already granted, the Remuneration Committee of the Company has approved that, the stock options already granted aggregating to 12,95,000 options be re-priced at Rs.105.75/-10 Jul · Management
Export-Import Bank of India, Mumbai has nominated Mr. John Mathew as Nominee Director in place of Mr. D G Prasad on the Board of the Company with effect from July 01, 2009.2 Jul · Updates
Partial repurchase and cancellation of Convertible Bonds. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
24 Jun · Meeting
Vide its letter dated June 24, 2009, that: "The shareholders at the Extraordinary General Meeting held today have approved the Special Resolution for transferring the balance in Securities Premium Account to the Reserve for Business Restructuring in terms of the Scheme, to such extent as may be determined by the Board".24 Jun · Business
The Equity Shareholders of the Company at their meeting convened as per the order of the Hon'ble High Court of Judicature at Bombay, held on June 24, 2009 have approved the Scheme of Arrangement between Grandix Pharmaceuticals Limited, Grandix Laboratories Limited, Global Remedies Limited and Quantum Remedies Private Limited ('Transferor Companies') with Strides Arcolab Limited (Transferee Company)23 Jun · Results
Based on the Scrutinizer's Report dated June 23, 2009, the resolutions seeking approval of the shareholders through Postal Ballot concerning the following matter have been carried out with requisite majority. a) Ordinary resolution for transfer of Specialties Pharmaceuticals Business of the Company to Strides Specialties Private Limited, a wholly owned subsidiary of the Company. b) Ordinary resolution for transfer of R&D Business of the company to Strides Technology & Research Private Limited, a wholly-owned subsidiary of the Company. c) Special resolution for re-pricing of unexercised options issued under Strides Arcolab ESOP 2006 and Strides Arcolab ESOP 2008 Schemes. d) Special resolution for amendment of Strides Arcolab ESOP 2006 scheme for inclusion of 'surrender clause'. e) Special resolution for amendment of Strides Arcolab ESOP 2008 scheme for inclusion of 'surrender clause'. f) Special resolution for re-appointment of Mr. Arun Kumar as Managing Director upon existing terms and conditions for a further period of 5 years effective from May 24, 2009.
May 2009
28 May · Notice of Meeting / others
By an order made on May 08, 2009, the Hon'ble High Court of Judicature at Bombay has directed that a meeting of the Equity Shareholders of Strides Arcolab Limited, the Applicant Company, be convened and held on June 24, 2009 for the purpose of considering, and if thought fit, approving with or without modification(s), the arrangement embodied in the Composite Scheme of Arrangement of Global Remedies Limited, Grandix Pharmaceuticals Limited, Grandix Laboratories Limited and Quantum Remedies Private Limited ('Transferor Companies') and Strides Arcolab Limited ('Transferee Company') and their respective Shareholders and Creditors. The Scheme provides for the amalgamation of the Transferor Companies with the Transferee Company. The Company has also convened an EGM of the equity shareholders on June 24, 2009 for seeking approval of members for transfer of balance in the Securities Premium Account of the Company to Reserves for Business Restructuring. The copies each of the Notice of the Court Convened Meeting and the EGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 May · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 May · Allotment of Warrants
Pursuant to the approval accorded by the Shareholders at their Extraordinary General Meeting held on May 13, 2009, in-principle approval received from Bombay Stock Exchange Limited and National Stock Exchange of India Limited and in accordance with Chapter XIII of SEBI (Disclosure and Investor Protection) Guidelines, 2000, the Board of Directors of the Company has allotted 6,200,000 warrants at a price of Rs.91.15 per warrant, on preferential basis to the following entity / persons who are part of the Promoter Group, entitling the warrant holder to apply for an equivalent number of fully paid-up equity share of Rs.10 each of the Company at any time during 18 months from the date of issue. Name: Netequity Ventures Private Limited - No. of warrants:6,180,000;Name:Mr. G. Purushothaman Pillai - No. of warrants:10,000;Name:Mr. Mohana Kumar Pillai - No. of warrants:10,00021 May · Meeting
Notice of Postal Ballot (along with explanatory statement) seeking approval of the shareholders for: (1) Transfer of Specialties Pharmaceuticals Business of the Company to Strides Specialties Private Limited, a wholly owned subsidiary of the Company. (2) Transfer of R&D Business of the company to Strides Technology & Research Private Limited, a wholly-owned subsidiary of the Company. (3) Re-pricing of unexercised options issued under Strides Arcolab ESOP 2006 and Strides Arcolab ESOP 2008 Schemes. (4) Amendment of Strides Arcolab ESOP 2006 scheme for inclusion of 'surrender clause'. (5) Amendment of Strides Arcolab ESOP 2008 scheme for inclusion of 'surrender clause'.(6) Re-appointment of Mr. Arun Kumar as Managing Director upon existing terms and conditions for a further period of 5 years effective from May 24, 2009. The copy of Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Meeting
Minutes of the Annual General Meeting of the Company held on April 24, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 May · Business
Press release dated May 15, 2009 titled "Strides Arcolab announces 2 ANDA approvals for Adenosine Injection USP and Meloxicam Tablets USP-Total approvals in Steriles space at 16 and Orals space at 12". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements. For more details click here.13 May · Meeting
Vide its letter dated May 13, 2009 that "the shareholders at the Extraordinary General Meeting held today, have approved the issue of upto 6,200,000 warrants convertible into equivalent number of equity shares on a preferential basis to Promoters /Promoter Group/their associates in accordance with SEBI(Disclosure and Investor Proctection) Guidelines, 2000 at a price(inclusive of premium) not less than the minimum price arrived at in accordance with the provisions of Chapter XIII of SEBI DIP Guidelines".